Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild

Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion Japanese yen ($610 million) hit linked to its precautionary antibody-drug Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a $610 million hit linked to its precautionary antibody-drug conjugate manufacturing strategy. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards…

Source: FiercePharma